- Home
- BIIB vs ERIC Comparison
BIIB vs ERIC Comparison
Compare BIIB & ERIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ERIC
- Stock Information
- Founded
- BIIB 1978
- ERIC 1876
- Country
- BIIB United States
- ERIC Sweden
- Employees
- BIIB N/A
- ERIC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ERIC Radio And Television Broadcasting And Communications Equipment
- Sector
- BIIB Health Care
- ERIC Technology
- Exchange
- BIIB Nasdaq
- ERIC Nasdaq
- Market Cap
- BIIB 18.7B
- ERIC 31.7B
- IPO Year
- BIIB 1991
- ERIC N/A
- Fundamental
- Price
- BIIB $149.94
- ERIC $9.47
- Analyst Decision
- BIIB Buy
- ERIC Hold
- Analyst Count
- BIIB 25
- ERIC 1
- Target Price
- BIIB $183.05
- ERIC $9.80
- AVG Volume (30 Days)
- BIIB 1.6M
- ERIC 19.2M
- Earning Date
- BIIB 10-30-2025
- ERIC 10-14-2025
- Dividend Yield
- BIIB N/A
- ERIC 2.06%
- EPS Growth
- BIIB 31.67
- ERIC N/A
- EPS
- BIIB 10.45
- ERIC 0.78
- Revenue
- BIIB $9,997,000,000.00
- ERIC $25,502,929,121.00
- Revenue This Year
- BIIB $2.03
- ERIC N/A
- Revenue Next Year
- BIIB N/A
- ERIC $0.71
- P/E Ratio
- BIIB $14.34
- ERIC $12.11
- Revenue Growth
- BIIB 3.36
- ERIC N/A
- 52 Week Low
- BIIB $110.04
- ERIC $6.64
- 52 Week High
- BIIB $187.58
- ERIC $9.87
- Technical
- Relative Strength Index (RSI)
- BIIB 59.16
- ERIC 67.93
- Support Level
- BIIB $141.70
- ERIC $9.38
- Resistance Level
- BIIB $147.48
- ERIC $9.62
- Average True Range (ATR)
- BIIB 3.53
- ERIC 0.20
- MACD
- BIIB -0.16
- ERIC 0.05
- Stochastic Oscillator
- BIIB 64.00
- ERIC 76.86
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ERIC Ericsson
Ericsson provides telecom equipment and services that are primarily used to build and operate mobile networks. The firm divides its business into three segments: networks, cloud and software services, and enterprise. Wireless carriers have traditionally been the firm's primary customers, but it is pushing to cater more to enterprises as well, as both try to take advantage of 5G capabilities and utilize "as-a-service" communications platforms. The company also licenses its patents to handset manufacturers.